
Clinical Takeaways from CGM Data: Engagement, Technology Fatigue, and Follow-Up
Higher CGM use links to bigger A1c drops in type 2 diabetes, revealing how monitoring and meds like GLP-1s drive better control.
Episodes in this series

In this episode, 'Clinical Takeaways from CGM Data: Engagement, Technology Fatigue, and Follow-Up,' the diabetes and managed care experts explore the following questions:
1. What are your main takeaways from this retrospective, cross-sectional study, and how will this carry over into your clinical practice?
2. The authors suggest that 6 months post-CGM initiation is a critical inflection point for counseling. Does this align with what you observe clinically, and what does your current follow-up structure look like around CGM initiation?
Estay Greene and Victoria Bouhairie examined the clinical implications of the retrospective study, noting that the most significant A1C reductions occurred within the first three months of CGM use as patients identified and corrected key behavioral drivers of hyperglycemia, such as late-night eating, missed doses, and dietary choices. The experts discussed how engagement tends to level off around the six-month mark once the most impactful behavioral changes have been made, making this a critical inflection point for clinician intervention through motivational interviewing and active patient re-engagement. Dr. Bouhairie also outlined her structured follow-up approach, which includes an initial two-to-four week check-in to address device questions and sensitivity issues, followed by visits every three months throughout the first year to sustain engagement and monitor progress.
Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.
The final episode in this series, 'CGM for All: Key Takeaways for Patients, Providers, and Payers,' features the panelists advancing their conversation on diabetes and focusing on the implications of CGM use in non-insulin users, best practices for multidisciplinary CGM education, and the overarching takeaways from the 2026 ADA guidelines for patients, providers, and payers alike.























